Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.

Kim SB, Meric-Bernstam F, Kalyan A, Babich A, Liu R, Tanigawa T, Sommer A, Osada M, Reetz F, Laurent D, Wittemer-Rump S, Berlin J.

Target Oncol. 2019 Oct;14(5):591-601. doi: 10.1007/s11523-019-00670-4.

2.

Exact invariant solution reveals the origin of self-organized oblique turbulent-laminar stripes.

Reetz F, Kreilos T, Schneider TM.

Nat Commun. 2019 May 23;10(1):2277. doi: 10.1038/s41467-019-10208-x.

3.

Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.

Sommer A, Kopitz C, Schatz CA, Nising CF, Mahlert C, Lerchen HG, Stelte-Ludwig B, Hammer S, Greven S, Schuhmacher J, Braun M, Zierz R, Wittemer-Rump S, Harrenga A, Dittmer F, Reetz F, Apeler H, Jautelat R, Huynh H, Ziegelbauer K, Kreft B.

Cancer Res. 2016 Nov 1;76(21):6331-6339. Epub 2016 Aug 19.

Supplemental Content

Support Center